These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 38630392)

  • 1. PI3K/AKT/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer.
    Zhang HP; Jiang RY; Zhu JY; Sun KN; Huang Y; Zhou HH; Zheng YB; Wang XJ
    Breast Cancer; 2024 Jul; 31(4):539-551. PubMed ID: 38630392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
    Costa RLB; Han HS; Gradishar WJ
    Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway.
    Massihnia D; Galvano A; Fanale D; Perez A; Castiglia M; Incorvaia L; Listì A; Rizzo S; Cicero G; Bazan V; Castorina S; Russo A
    Oncotarget; 2016 Sep; 7(37):60712-60722. PubMed ID: 27474173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
    Coussy F; El Botty R; Lavigne M; Gu C; Fuhrmann L; Briaux A; de Koning L; Dahmani A; Montaudon E; Morisset L; Huguet L; Sourd L; Painsec P; Chateau-Joubert S; Larcher T; Vacher S; Melaabi S; Salomon AV; Marangoni E; Bieche I
    J Hematol Oncol; 2020 Feb; 13(1):13. PubMed ID: 32087759
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges.
    Khan MA; Jain VK; Rizwanullah M; Ahmad J; Jain K
    Drug Discov Today; 2019 Nov; 24(11):2181-2191. PubMed ID: 31520748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Inhibition of the PI3K/Akt/mTOR Signaling Axis: Potential for Sarcoma Therapy.
    Wani AK; Singh R; Akhtar N; Prakash A; Nepovimova E; Oleksak P; Chrienova Z; Alomar S; Chopra C; Kuca K
    Mini Rev Med Chem; 2024; 24(16):1496-1520. PubMed ID: 38265369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer.
    Wen W; Marcinkowski E; Luyimbazi D; Luu T; Xing Q; Yan J; Wang Y; Wu J; Guo Y; Tully D; Han ES; Yost SE; Yuan Y; Yim JH
    Cells; 2019 Aug; 8(9):. PubMed ID: 31480338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
    He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
    Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PI3K-AKT-mTOR inhibitors in breast cancers: From tumor cell signaling to clinical trials.
    Dey N; De P; Leyland-Jones B
    Pharmacol Ther; 2017 Jul; 175():91-106. PubMed ID: 28216025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
    Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
    Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
    Araki K; Miyoshi Y
    Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PI3K/mTOR dual inhibitor NVP-BEZ235 stimulates mutant p53 degradation to exert anti-tumor effects on triple-negative breast cancer cells.
    Cai J; Xia J; Zou J; Wang Q; Ma Q; Sun R; Liao H; Xu L; Wang D; Guo X
    FEBS Open Bio; 2020 Apr; 10(4):535-545. PubMed ID: 32027103
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Loss of PTEN in high grade advanced stage triple negative breast ductal cancers in African American women.
    Khan F; Esnakula A; Ricks-Santi LJ; Zafar R; Kanaan Y; Naab T
    Pathol Res Pract; 2018 May; 214(5):673-678. PubMed ID: 29653745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
    Ediriweera MK; Tennekoon KH; Samarakoon SR
    Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies.
    Barrett D; Brown VI; Grupp SA; Teachey DT
    Paediatr Drugs; 2012 Oct; 14(5):299-316. PubMed ID: 22845486
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of Akt/mTOR pathway overcomes intrinsic resistance to dasatinib in triple-negative breast cancer.
    Haga Y; Higashisaka K; Yang L; Sekine N; Lin Y; Tsujino H; Nagano K; Tsutsumi Y
    Biochem Biophys Res Commun; 2020 Dec; 533(4):672-678. PubMed ID: 33036754
    [TBL] [Abstract][Full Text] [Related]  

  • 17. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors.
    Lehmann BD; Bauer JA; Schafer JM; Pendleton CS; Tang L; Johnson KC; Chen X; Balko JM; Gómez H; Arteaga CL; Mills GB; Sanders ME; Pietenpol JA
    Breast Cancer Res; 2014 Aug; 16(4):406. PubMed ID: 25103565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rhizoma Amorphophalli inhibits TNBC cell proliferation, migration, invasion and metastasis through the PI3K/Akt/mTOR pathway.
    Wu C; Qiu S; Liu P; Ge Y; Gao X
    J Ethnopharmacol; 2018 Jan; 211():89-100. PubMed ID: 28962890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness.
    De P; Sun Y; Carlson JH; Friedman LS; Leyland-Jones BR; Dey N
    Neoplasia; 2014 Jan; 16(1):43-72. PubMed ID: 24563619
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Therapeutic Potential of PI3K/Akt/mTOR Inhibitors in Breast Cancer: Rational and Progress.
    Bahrami A; Khazaei M; Shahidsales S; Hassanian SM; Hasanzadeh M; Maftouh M; Ferns GA; Avan A
    J Cell Biochem; 2018 Jan; 119(1):213-222. PubMed ID: 28513879
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.